<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230916059439N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-01-21</date_registration>
      <primary_sponsor>Aseman-e-Sharg Health Home Company</primary_sponsor>
      <public_title>The Efficacy of Topical Application of Honey Health Gel in Combination with Collagen on Diabetic Foot Ulcers</public_title>
      <acronym></acronym>
      <scientific_title>The Efficacy of Topical Application of Honey Health Gel in Combination with Collagen on Diabetic Foot Ulcers in Patients Referring to Medical Centers</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88534</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: the sampling method is based on the available method according to the criteria for entering the research . first , patients with type of diabetes that have the inclusion criteria in the study will be selected by available method and then randomly assigned to the three groups by using the three permutation blocks (ABC, CAB, BAC ) . the choice of blocks is done randomly using dice throwing to sufficient sample size ( 96 people ) . the samples that were selected by available sampling were selected according to the selected blocks in group A for the intervention of Honey Health Gel and B for the combination of Honey Health Gel with collagen and C for control , Blinding description: prior to the study , informed consent of the company to participate in the study and eventual inclusion in one of the study groups ( randomly ) will be obtained . according to the method of random allocation that was mentioned in the sampling method , the patient was placed in group a or b or c .  moreover , the researcher has trained the information about the wound that is without any knowledge about the wound condition .</study_design>
      <phase>3</phase>
      <hc_freetext>Diabetic foot wound infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: n addition to the standard method, Honey Health gel combined with collagen will be applied every other day and once every turn for 28 days. The intervention involves placing a layer of Honey Health gel mixed with collagen on the wound after cleaning and washing the wound, which will then be covered with a layer of gauze. In other words, Honey Health gel and collagen powder are mixed at a ratio of 3:2 on a sterile surface, and the resulting mixture is applied evenly on the wound using sterile forceps, and finally covered with a layer of gauze. Producers: Pars Takrokh  and Treatta pharmaceutical company. Intervention 2: Intervention group: In addition to the standard method, Honey Health gel alone will be applied every other day and once every turn for 28 days. The intervention involves placing a layer of Honey Health gel on the wound after cleaning and washing the wound, which will then be covered with a layer of gauze.  Producer: Pars Takrokh pharmaceutical company. Intervention 3: Control group: In the control group, the routine hospital care method will be used, which includes wound washing with normal saline and dressing with moist gauze.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza Ghorbani Noughabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Asiasi Road (Roadside), Gonabad University of Medical Sciences</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>969169996</zip>
        <telephone>+98 915 925 9581</telephone>
        <email>rezaghorbani8678@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Moosa Sajjadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Gonabad University of Medical Sciences, near Asian Road, Gonabad</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>969169996</zip>
        <telephone>+98 915 533 6294</telephone>
        <email>Sajjadi1975@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness and consent to participate in the study and completion of the informed consent form
Age between 18 and 60 years
Absence of diseases such as leukemia and immunodeficiency
Use of the same (identical) antibiotic among participants
Diabetic foot wound infection of grade 2, confirmed by an infectious disease specialist and based on IDSA criteria
Diabetes confirmed by an infectious disease specialist
Wound size grade 3 according to the Bates–Jensen wound assessment tool
Presence of only one diabetic foot ulcer</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient death
Unwillingness to continue participation during the study
Occurrence of any disorder or specific condition during the study that precludes the use of Honey Health gel dressing in combination with collagen, such as concurrent use of any dressing other than the intervention dressing specified in this study
Necessity of using any pharmacological or non‑pharmacological intervention affecting diabetic foot wound infection
Wound size grade 5 according to the Bates–Jensen wound assessment tool</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L08.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Local infection of the skin and subcutaneous tissue, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: n addition to the standard method, Honey Health gel combined with collagen will be applied every other day and once every turn for 28 days. The intervention involves placing a layer of Honey Health gel mixed with collagen on the wound after cleaning and washing the wound, which will then be covered with a layer of gauze. In other words, Honey Health gel and collagen powder are mixed at a ratio of 3:2 on a sterile surface, and the resulting mixture is applied evenly on the wound using sterile forceps, and finally covered with a layer of gauze. Producers: Pars Takrokh  and Treatta pharmaceutical company</i_keyword>
      <i_keyword>Intervention group: In addition to the standard method, Honey Health gel alone will be applied every other day and once every turn for 28 days. The intervention involves placing a layer of Honey Health gel on the wound after cleaning and washing the wound, which will then be covered with a layer of gauze.  Producer: Pars Takrokh pharmaceutical company</i_keyword>
      <i_keyword>Control group: In the control group, the routine hospital care method will be used, which includes wound washing with normal saline and dressing with moist gauze.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Diabetic foot wound infection. Timepoint: Before the intervention and immediately after the intervention. Method of measurement: IDSA tool and Bates‑Jensen tool.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Aseman-e-Sharg Health Home Company</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-12-29</approval_date>
        <contact_name>Ethics Committee of Gonabad University of Medical Sciences</contact_name>
        <contact_address>Research and Technology Vice-Chancellor of Gonabad University of Medical Sciences,near Asian Road, Gonabad, Khorasan Razavi Gonabad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
